KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Liabilities (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Total Liabilities for 6 consecutive years, with $343.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 17.05% year-over-year to $343.3 million, compared with a TTM value of $343.3 million through Dec 2025, down 17.05%, and an annual FY2025 reading of $343.3 million, down 17.05% over the prior year.
  • Total Liabilities was $343.3 million for Q4 2025 at Recursion Pharmaceuticals, down from $352.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $413.8 million in Q4 2024 and bottomed at $55.9 million in Q2 2021.
  • Average Total Liabilities over 5 years is $217.3 million, with a median of $199.8 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 67.28% in 2021, then surged 324.89% in 2022.
  • Year by year, Total Liabilities stood at $67.4 million in 2021, then skyrocketed by 219.67% to $215.5 million in 2022, then dropped by 11.7% to $190.3 million in 2023, then skyrocketed by 117.5% to $413.8 million in 2024, then dropped by 17.05% to $343.3 million in 2025.
  • Business Quant data shows Total Liabilities for RXRX at $343.3 million in Q4 2025, $352.6 million in Q3 2025, and $383.2 million in Q2 2025.